Lung Cancer Therapeutics Market Analysis and Forecast to 2032: By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), Cancer Type (Non-small Cell Lung Cancer, Small Cell Lung Cancer), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Onli

Lung Cancer Therapeutics Market Analysis and Forecast to 2032: By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), Cancer Type (Non-small Cell Lung Cancer, Small Cell Lung Cancer), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and Region

The global lung cancer therapeutics market was valued at USD 18.3 billion in 2021 and it is anticipated to grow further till USD 74.1 billion by 2031, at a CAGR of 15.0% during the forecast period.

The uncontrolled proliferation of cells in the lung tissues causes lung cancer, a deadly lung tumor. The main risk factor for lung cancer development is cigarette smoking. Lung cancer can also be brought on by smoking tobacco for a long time. Using bronchoscopy or CT guidance, a biopsy is performed to confirm the diagnosis of lung cancer. Therefore, chemotherapy, radiation, immunotherapy, surgery, etc. can all be used to treat lung cancer.
Global Lung Cancer Therapeutics Market Scope and Report Structure
Market Trends and Drivers
Rising cancer awareness in both developed and developing countries, the introduction of new medical diagnostic tools and cutting-edge treatments, and an increase in lung cancer diagnoses have all contributed to the market expansion for lung cancer medicines. The expansion of the global market is also being boosted by this, along with rising investments made by leading players in research and development activities. Due to an increase in lung cancer cases, more attention is being paid to R&D projects, which is what is causing the market to alter.
Market Restraints and Challenges
The side effects of drug therapies and the high cost of the therapies have been hindering the growth of the market.

Global Lung Cancer Therapeutics Market Segmental Overview
The report analyses the global lung cancer therapeutics market based on the therapy, cancer type, distribution channel, and region.

Global Lung Cancer Therapeutics Market by Therapy

Based on therapy, it is segmented into targeted therapy, immunotherapy, chemotherapy. The targeted therapy segment is anticipated to dominate the market during the forecast period. The key factors such as increasing R&D advances leading to greater adoption of sophisticated and advanced therapies such as immunotherapy coupled with the increasing prevalence of lung cancer is boosting the growth of the market.

Global Lung Cancer Therapeutics Market by Cancer Type


Based on the cancer type, it is segmented into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment is anticipated to dominate the market during the forecast period. The increasing prevalence of all types of cancers are prevalent in the general population and lung cancer is one of the most common forms of cancer. The rising prevalence and rising incidence of lung cancer across all demographics and across all age groups have led to increasing demand for lung cancer therapeutics during the forecast period.

Global Lung Cancer Therapeutics Market by Distribution Channel


Based on the distribution channel, it is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment is anticipated to dominate the market during the forecast period. The key factors such as the increasing regulatory approvals and the adoption of advanced therapeutics are boosting the growth of the market.

Geographical Analysis of the Global Lung Cancer Therapeutics Market



Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America and Europe dominated the market during the forecast period. According to lung disease research funding coupled with high incidence rate rise in the aging population coupled with the advent of new treatment therapies such as targeted drug therapy, and stereotactic are boosting the growth of the market.
Major Players in the Global Lung Cancer Therapeutics Market
The key players studied in the report are Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation, AstraZeneca, Pfizer Inc., Sanofi, Novartis AG, Astellas, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc. (Takeda), and Merck Sharp & Dohme Corp. among others.
COVID-19 Impact
The world is still in danger from the COVID-19 pandemic, especially individuals who already have lung disease. The pandemic has presented many difficulties for people with lung cancer. At the Fifth Affiliated Hospital of Sun Yat-sen University, approximately 95 patients out of 161 had delayed their return visit in April 2020, and 47 cases were finally designated as having delayed admission during the pandemic and having to discontinue or delay their regular anticancer treatments, according to an article published in September 2020 titled "The impact of the COVID-19 pandemic on lung cancer patients."
Recent Development

June 2022, Novartis received approval from European Commission for Tabrecta for the treatment of METex 14 skipping advanced non-small cell lung cancer.
April 2022, Astra Zeneca and Daiichi Sankyo received the acceptance of the supplemental Biologics License Application for Enhertu for the treatment of adult patients in the United States with unresectable or metastatic non-small cell lung cancer, by the United States Food and Drug Administration.
March 2022, Astra Zeneca, PATH and Qure.ai have formed a new partnership to enhance lung health across low to middle income nations. These three firms will form alliances to develop a framework for early detection of lung cancer in patients that are undergoing chest screening to detect tuberculosis, with the use of advanced artificial intelligence technology.
March 2022, Known Medicine, a fast-growing biotechnology vendor focused on discovering effective cancer drugs, has partnered with Duke University to estimate the drug efficacy for patients suffering from lung cancer.

Frequently Asked Questions
Q1. How big is the Lung Cancer Therapeutics market?

Ans. The global Lung Cancer Therapeutics market size was USD 18.3 billion in 2021 and is anticipated to reach USD 74.1 billion in 2031, growing at a rate of 15.0% from 2022 to 2031.

Q2. What is the Lung Cancer Therapeutics market growth rate?

Ans. The growth rate of the Lung Cancer Therapeutics market is 15.0%.

Q3. Which region holds a major market share for the Lung Cancer Therapeutics market?

Ans. North America holds a major market share of the Lung Cancer Therapeutics market in 2021.

Q4. Which segment accounted for the largest Lung Cancer Therapeutics market share?

Ans. By therapy, targeted therapy segment accounted for the largest Lung Cancer Therapeutics market share.

Q5. Who are the key players in the Lung Cancer Therapeutics market?

Ans. The global Lung Cancer Therapeutics market report includes players such as Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation, AstraZeneca, Pfizer Inc., Sanofi, Novartis AG, Astellas, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc. (Takeda), and Merck Sharp & Dohme Corp. among others.

Q6. What are the factors driving the Lung Cancer Therapeutics market growth?

Ans. The major factors driving the growth of the market are the growing healthcare market in emerging countries.

Q7. What are the key growth strategies of Lung Cancer Therapeutics market players?

Ans. The key growth strategies of Lung Cancer Therapeutics market players are product launch and product approval.

Q8. Which region will provide more business opportunities for the Lung Cancer Therapeutics market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the Lung Cancer Therapeutics market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.